Jazz Pharmaceuticals PLC (JAZZ)
| Market Cap | 10.56B |
| Revenue (ttm) | 2.44B |
| Net Income (ttm) | 518.28M |
| Shares Out | 60.98M |
| EPS (ttm) | 9.07 |
| PE Ratio | 19.09 |
| Forward PE | 12.55 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $173.26 |
| Previous Close | $173.93 |
| Change ($) | -0.67 |
| Change (%) | -0.39% |
| Day's Open | 173.58 |
| Day's Range | 173.00 - 175.41 |
| Day's Volume | 341,356 |
| 52-Week Range | 107.59 - 189.00 |
Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.
DUBLIN, July 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (rec...
DUBLIN, July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021 after the close of ...
These 10 stocks to buy have strong free cash flow margins and are trading near the S&P 500's year-to-date return. The post 10 Stocks to Buy That Will Double in the Second Half of 2021 appeared first on ...
JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021
Big Pharmaceutical Companies That Are Top Medicinal Cannabis Stocks The post Best Medical Marijuana Stock To Buy In 2021? 2 With Long Term Potential Right Now appeared first on Marijuana Stocks | Cannab...
DUBLIN, July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m.
Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In ...
These companies can be serious moneymakers for discount-seeking investors.
Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
The FDA has approved Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in ...
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze ™ (asparaginase erwinia chrysanthemi (recomb...
They are great options whether you are investing for the short or long term.
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older wit...
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 1 Somewhat Bullish 1 1 0 0 Indiff...
ABT, BNL, ITRG, JAZZ, and MANU have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2021
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has updated its full-year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company acquired on May 5. Forecasts total net product...
DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company a...
2 Marijuana Stocks To Add To Your Watchlist In June The post 2 Marijuana Stock To Add To Your Watchlist This Week appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding I...
According to the GuruFocus discounted cash flow calculator as of June 16, the following companies have a high margin of safety and have grown their margins over a 10-year period.
If screening the market for value opportunities, investors may want to consider the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earning...
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned defensive companies have grown their book value per share over the past decade through June 14.
DUBLIN, June 14, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed with consult...
DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials wil...
NEW YORK, June 4, 2021 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of California...
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
2 Biotech Cannabis Stocks To Watch Next Month As marijuana stocks continue… The post 2 Biotech Cannabis Stocks To Watch In June 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. R...
DUBLIN, May 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the Jef...
These Could Be Cannabis Investments For Your Long Term Portfolio The post The Best Long Term Cannabis Stocks Right Now? 2 For To Watch In May appeared first on Marijuana Stocks | Cannabis Investments an...
DUBLIN, May 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clin...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH).
Jazz (JAZZ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
The developer of cannabis-based medications is now under new ownership.
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, develo...
Jazz (JAZZ) delivered earnings and revenue surprises of 6.23% and 0.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, May 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the foll...
DUBLIN, May 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021. "Demand for Xywav is...
DUBLIN, April 29, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the closing of its previously announced offering (the "Offering") of $1.5 billion...
Jazz is about to get the top cannabis-derived drug on the market, in addition to a robust pipeline.
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Are These Top Cannabis Stocks To Invest In Right Now? The post Looking For Marijuana Stocks To Buy On Robinhood? 2 For Your Watchlist Next Week appeared first on Marijuana Stocks | Cannabis Investments ...
DUBLIN, April 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 billion...
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the "Issuer"...
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) ora...
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narc... [Read more...]
| Industry Biotechnology | IPO Date Jun 1, 2007 |
| Stock Exchange NASDAQ | Ticker Symbol JAZZ |
Financial Performance
In 2020, JAZZ's revenue was $2.36 billion, an increase of 9.34% compared to the previous year's $2.16 billion. Earnings were $238.62 million, a decrease of -54.41%.
Analyst Forecasts
According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 207.12, which is an increase of 19.54% from the latest price.